Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Part of paid clinical trials in New York, New York.

Sponsor: Columbia University
Study ID: NCT07433673
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Colon and Rectal Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Cemiplimab — DRUG
intravenous 300mg

Study Details

This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.

Key Dates

Start date: Aug 31, 2026
Status verified: Feb 2026
Primary completion: Jan 31, 2028
Completion: Jan 31, 2029

Study Design

Enrollment: 20 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Cemiplimab
All study participants will receive cemiplimab in addition to chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel).

Primary Outcome Measure

Rate of conversion to resectable disease and subsequent surgical resection [ Time Frame: 6 months from start of study treatment ]

Central Contacts

Research Nurse Navigator
212-342-5162
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Columbia University Irving Medical Center	New York	New York	10032	Research Nurse Navigator [email protected] 212-342-5162 Linda Wu, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site

Columbia University Irving Medical Center· New York, NY